Compare Johnson & Johnson (JNJ) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Total World Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $260.9 (market cap $626.09B), while Vanguard Total World Stock Index Fund ETF trades at $161.49. The key difference: Johnson & Johnson pays a 2.06% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| JNJ | VT | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Broad Market / Factor |
52-Week High | $267.24 | $161.30 |
52-Week Low | $172.78 | $132.19 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
VT trades at $161.59, up 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF's broad diversification across over 10,000 global stocks provides stability, though RSI levels indicate potential overbought conditions. Recent news highlights institutional activity, including Barry Investment Advisors reducing its stake by 18.7% in Q2 2026 (SEC filing, August 10, 2026).
Outlook remains positive due to global exposure and low expense ratio, but risks include trade war uncertainties and seasonal volatility. Analysts note fair valuation with a mid-to-high teens P/E and 11.4% long-term EPS growth (Seeking Alpha, July 25, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
